Mangoceuticals (MGRX) Liabilities and Shareholders Equity (2023 - 2025)
Historic Liabilities and Shareholders Equity for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to $16.5 million.
- Mangoceuticals' Liabilities and Shareholders Equity rose 1176.15% to $16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.5 million, marking a year-over-year increase of 13739.32%. This contributed to the annual value of $15.4 million for FY2024, which is 136275.35% up from last year.
- Latest data reveals that Mangoceuticals reported Liabilities and Shareholders Equity of $16.5 million as of Q3 2025, which was up 1176.15% from $20.8 million recorded in Q2 2025.
- In the past 5 years, Mangoceuticals' Liabilities and Shareholders Equity ranged from a high of $21.8 million in Q1 2025 and a low of $301447.0 during Q1 2024
- In the last 3 years, Mangoceuticals' Liabilities and Shareholders Equity had a median value of $15.0 million in 2024 and averaged $11.1 million.
- Examining YoY changes over the last 5 years, Mangoceuticals' Liabilities and Shareholders Equity showed a top increase of 711647.82% in 2025 and a maximum decrease of 1176.15% in 2025.
- Mangoceuticals' Liabilities and Shareholders Equity (Quarter) stood at $1.1 million in 2023, then soared by 1362.75% to $15.4 million in 2024, then grew by 7.56% to $16.5 million in 2025.
- Its Liabilities and Shareholders Equity stands at $16.5 million for Q3 2025, versus $20.8 million for Q2 2025 and $21.8 million for Q1 2025.